INTRODUCTION {#s1}
============

PC is a highly malignant digestive tract disease with difficult early diagnosis and treatment. In almost 90% of patients, it originates from the epithelial gland ductal carcinoma \[[@R1], [@R2]\]. In the US, the five-year survival rate of PC remains as low as 6% \[[@R3]\]. The low survival rate is attributed to several factors, perhaps the most important of which is the late stage and metastasis when most patients are diagnosed \[[@R1]--[@R3]\]. Unfortunately, most patients are asymptomatic until it develops to an advanced stage.

The most well-established risk factor for PC is cigarette smoking, \[[@R4]\]. Chronic pancreatitis \[[@R5]\], diabetes persisting more than 20 years \[[@R6]\], high body mass index (BMI), and centralized fat distribution \[[@R7]\]. Previous studies have suggested four major driver genes of PC: *KRAS* (Kras proto-oncogene, GTPase), *CDKN2A* (cyclin-dependent kinase inhibitor 2A), *TP53* (tumor protein p53), and *SMAD4* (SMAD family member 4). These four genes are referred to as mutation driver genes of PC \[[@R3], [@R8]\]. However, these genes can only explain parts of pancreatic tumorigenesis; these genetic mutations are not present in many other patients with PC. Therefore, epigenetic drivers were put forward. Epigenetic drivers mean that epigenetic changes could alter gene expression, leading to the occurrence of tumors. They are now acknowledged as a universal feature of tumorigenesis \[[@R8]\]. Cancer-testis (CT) genes, whose expression is restricted to germ cells and is often reactivated and aberrantly expressed in cancers, are a group of epigenetic driver genes \[[@R9], [@R10]\]. Recently, patient-derived xenograft models of pancreatic ductal adenocarcinoma (PDAC) showed that JQ1, an inhibitor of CT genes in the bromodomain and extraterminal (BET) protein family (*BRDT*), suppresses PDAC development by inhibiting both MYC (v-myc avian myelocytomatosis viral oncogene homolog) activity and inflammatory signals \[[@R11]\]. This provided new insight into the molecular targets of PC. These findings all suggested that CT genes might play an important role in molecular targeted therapy of PC.

Recently, we found that *STK31* (serine/threonine kinase 31, also known as *TDRD8*) might be a novel CT gene in PC \[[@R10]\]. As a Tudor family member, *STK31* contains an STK domain and a Tudor domain, and participates in cell cycle regulation \[[@R12]\]. In mice, the homologous protein of STK31 is restricted to germ cells \[[@R13], [@R14]\] and is highly expressed in spermatogonia meiosis \[[@R13], [@R15], [@R16]\]. Moreover, *STK31* has been detected in colorectal cancer and is activated by demethylation \[[@R14]\]. In Caco2 and SW1116 colorectal cancer cells, *STK31* knockdown enhanced cell differentiation capacity, indicating that *STK31* maintains low differentiation in colorectal cancer cells \[[@R12], [@R14], [@R16]\].

In the present study, we deciphered the expression pattern of *STK31* and attempted to confirm whether it will be a good biomarker aiding clinical diagnosis and prognosis of PC. We also attempted to uncover the regulatory mechanisms and gene network of *STK31* in PC.

RESULTS {#s2}
=======

Tissue expression patterns and role of *STK31* in PC {#s2_1}
----------------------------------------------------

To determine whether *STK31* could be assigned to the CT genes expressed in PC, we first evaluated its expression pattern in normal human tissues including pancreas using transcriptomic data deposited in the Genotype-Tissue Expression Project (GTEx). *STK31* was mainly expressed in the testis (Figure [1A](#F1){ref-type="fig"}). The Human Protein Atlas (HPA) result was generally consistent with the GTEx data, showing that *STK31* was only expressed in the testis at both RNA and protein level (Figure [1B](#F1){ref-type="fig"} & [1D](#F1){ref-type="fig"}). Next, we evaluated *STK31* expression in PC specimens through bioinformatics analysis of RNA sequencing (RNA-seq) of The Cancer Genome Atlas (TCGA) PAAD data (178 PC samples), which indicated that *STK31* was elevated in about 85% of patients with PC (Figure [1C](#F1){ref-type="fig"}), which was also supported by the HPA (Figure [1E](#F1){ref-type="fig"}). These results confirm that *STK31* is a CT gene in PC.

![*STK31* tissue expression pattern\
*STK31* RNA expression in normal tissues from GTEx **(A)** and HPA **(B)**; *STK31* RNA expression in pancreatic cancer tissues from TCGA **(C)**; STK31 protein expression in normal tissues from HPA **(D)**; STK31 protein expression in pancreatic cancer tissues from HPA **(E)**. RPKM: Reads Per Kilobases per Millionreads; FPKM: Fragments Per Kilobase Million;](oncotarget-08-35154-g001){#F1}

Interestingly, *STK31* expression was significantly higher in patients with new neoplasm compared with patients without new neoplasm (*P* = 0.046, Figure [2A](#F2){ref-type="fig"}). We also found that patients at more advanced pathologic stages tended to express *STK31* (*P* = 0.002, Figure [2B](#F2){ref-type="fig"}). To explore the association of *STK31* expression and the survival time of patients with PC, Kaplan--Meier survival curves based on *STK31* expression were constructed, showing that patients who expressed *STK31* had poorer survival (log-rank: *P* = 0.0009, Figure [3](#F3){ref-type="fig"}).

![The association between *STK31* expression and clinical features of pancreatic cancer\
*STK31* expression was significantly higher in patients with new neoplasm compared patients without new neoplasm **(A)** and in more advanced pathologic stages than in earlier stages **(B)**.](oncotarget-08-35154-g002){#F2}

![The association between *STK31* expression and survival of patients with pancreatic cancer\
Patients with *STK31* expression (RSEM\>5, dotted line) had poorer survival than patients without *STK31* expression (RSEM≤5, solid line).](oncotarget-08-35154-g003){#F3}

The relationship between methylation, mutation, and *STK31* expression {#s2_2}
----------------------------------------------------------------------

In TCGA, almost one-fifth of patients with PC did not harbor the four major mutation driver genes in PC (*KRAS*, *CDKN2A*, *TP53*, *SMAD4*) (Figure [4A](#F4){ref-type="fig"}). Only 2% of patients carried *STK31* mutations. These results suggest another driving mode, such as epigenetic drivers, in PC. Further analysis showed that there was almost no histone modification in the *STK31* promoter region (2 kb upstream of the *STK31*) (<http://genome.ucsc.edu/cgi-bin/hgGateway,> Figure [4B](#F4){ref-type="fig"}). Interestingly, we found that methylation level (2 kb upstream of *STK31*) was negatively correlated with *STK31* expression (Pearson r=-0.634, Spearman r=-0.634, <http://www.cbioportal.org/index.do,> Figure [4C](#F4){ref-type="fig"}).

![The relationship between methylation, mutation, and *STK31* expression\
**(A)** Only 2% of patients with pancreatic cancer carried *STK31* mutations; almost one-third of patients with pancreatic cancer (black rectangle) did not carry the four major mutation driver genes (*KRAS*, *CDKN2A*, *TP53*, *SMAD4*). **(B)** There was almost no histone modification in the *STK31* promoter region (2 kb upstream of *STK31*)). **(C)** Methylation levels (2 kb upstream of *STK31*) were negatively correlated with *STK31* expression.](oncotarget-08-35154-g004){#F4}

The *STK31* gene network {#s2_3}
------------------------

We analyzed the relationship between *STK31* and 20,530 other genes. Seven hundred and fifty-seven genes were related with *STK31* (*P* \< 1 × 10^-6^), where *STK31* was strongly associated with piwi-like RNA-mediated gene silencing 1 (*PIWIL1*) (r = 0.50, *P* = 5.56 × 10^-15^, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). A total 487 genes over-represented KEYWORDS terms related to polymorphism (false discovery rate, FDR: *P* \< 0.001), representing genomic instability; only four Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (Table [1](#T1){ref-type="table"}), including tight junction, adherens junction, glycosphingolipid biosynthesis, and axon guidance, were significantly enriched (FDR: *P* = 0.006, 0.006, 0.023, and 0.036, respectively) according to the Database for Annotation Visualization and Integrated Discovery (DAVID) ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The Search Tool for the Retrieval of Interacting Genes (STRING 10.0) predicted physical interaction between *STK31* and the PIWI subfamily of Argonaute proteins (*PIWIL1*, *PIWIL3*, *PIWIL4*) and the Tudor family (*TDRD5*, *TDRD7*, *TDRD9*, *TDRD15*, *TDRKH*) (Figure [5](#F5){ref-type="fig"}).

###### GO and pathway enrichment analysis of *STK31*-related genes

  Category       Term                                                         Count   FDR P-value
  -------------- ------------------------------------------------------------ ------- -------------
  Keywords       Polymorphism                                                 487     3.10E-05
  Keywords       Alternative splicing                                         442     6.20E-06
  Keywords       Phosphoprotein                                               343     6.50E-08
  Keywords       Membrane                                                     289     2.40E-02
  Keywords       Cytoplasm                                                    231     2.10E-06
  Keywords       Nucleotide-binding                                           91      4.90E-03
  Keywords       Transferase                                                  89      7.80E-04
  Keywords       Ubl conjugation                                              87      4.30E-03
  Keywords       ATP-binding                                                  79      6.00E-04
  Keywords       Cytoskeleton                                                 72      3.60E-05
  Keywords       Cell cycle                                                   58      1.40E-08
  Keywords       Developmental protein                                        55      5.20E-03
  Keywords       Cell division                                                46      1.80E-10
  Keywords       Cell junction                                                44      1.40E-03
  Keywords       Kinase                                                       41      3.20E-02
  Keywords       Mitosis                                                      39      2.30E-11
  Keywords       Apoptosis                                                    36      5.90E-03
  Keywords       Chromosome                                                   32      3.30E-04
  Keywords       Glycosyltransferase                                          25      9.70E-05
  Keywords       Centromere                                                   24      1.70E-08
  Keywords       SH3 domain                                                   23      2.40E-04
  Keywords       Microtubule                                                  23      6.80E-03
  Keywords       Kinetochore                                                  20      2.50E-08
  Keywords       Motor protein                                                15      5.00E-03
  Keywords       Tight junction                                               14      2.30E-04
  Keywords       Tyrosine protein kinase                                      13      8.60E-03
  Keywords       Microsome                                                    13      2.60E-02
  Keywords       Chromosome partition                                         10      4.40E-04
  Keywords       Epidermolysis bullosa                                        7       2.20E-04
  Keywords       Basement membrane                                            7       3.20E-02
  GO analysis                                                                         
  MF             Protein kinase binding                                       32      4.90E-02
  CC             Cytoplasm                                                    239     2.60E-05
  CC             Cytosol                                                      176     9.00E-06
  CC             Extracellular exosome                                        150     9.90E-05
  CC             Nucleoplasm                                                  129     1.00E-02
  CC             Focal adhesion                                               30      1.20E-02
  CC             Midbody                                                      21      1.30E-05
  CC             Cell--cell junction                                          17      1.10E-02
  CC             Kinetochore                                                  16      1.20E-05
  CC             Condensed chromosome kinetochore                             16      1.50E-05
  CC             Bicellular tight junction                                    16      9.60E-04
  CC             Chromosome, centromeric region                               13      2.50E-05
  CC             Spindle pole                                                 12      2.60E-02
  CC             Spindle microtubule                                          10      1.40E-03
  CC             Brush border                                                 10      3.00E-03
  CC             Mitotic spindle                                              8       1.60E-02
  CC             Desmosome                                                    7       7.00E-03
  CC             Hemidesmosome                                                5       4.50E-03
  BP             Small GTPase--mediated signal transduction                   49      1.50E-02
  BP             Apoptotic process                                            41      4.00E-02
  BP             Cell division                                                37      6.60E-06
  BP             Mitotic cell cycle                                           36      5.90E-03
  BP             Mitotic nuclear division                                     32      3.50E-06
  BP             Cell proliferation                                           32      6.80E-03
  BP             Cell migration                                               20      6.60E-03
  BP             Cell junction assembly                                       19      1.30E-06
  BP             Ephrin receptor signaling pathway                            17      2.20E-04
  BP             Chromosome segregation                                       16      4.70E-05
  BP             Anterior/posterior pattern specification                     13      1.60E-02
  BP             Single organismal cell--cell adhesion                        13      3.00E-02
  BP             Epidermis development                                        12      3.50E-02
  BP             Cell--cell junction organization                             11      2.90E-02
  BP             Bicellular tight junction assembly                           10      6.10E-03
  BP             O-glycan processing                                          10      3.60E-02
  BP             Hemidesmosome assembly                                       7       9.10E-04
  BP             Mitotic sister chromatid segregation                         7       2.10E-02
  BP             Phosphatidylethanolamine acyl-chain remodeling               7       2.60E-02
  BP             Mitotic cytokinesis                                          7       4.60E-02
  BP             Branching involved in mammary gland duct morphogenesis       6       1.60E-02
  BP             Negative regulation of cellular glucuronidation              5       2.20E-02
  BP             Negative regulation of glucuronosyltransferase activity      5       2.20E-02
  BP             Negative regulation of fatty acid metabolic process          5       2.90E-02
  BP             Xenobiotic glucuronidation                                   5       2.90E-02
  pathway                                                                             
  KEGG_PATHWAY   Tight junction                                               16      6.80E-03
  KEGG_PATHWAY   Axon guidance                                                15      2.30E-02
  KEGG_PATHWAY   Adherens junction                                            12      7.40E-03
  KEGG_PATHWAY   Glycosphingolipid biosynthesis - lacto and neolacto series   7       3.00E-02

![The *STK31* gene network\
*STK31* interacts with the PIWI subfamily of Argonaute proteins (*PIWIL1*, *PIWIL3*, *PIWIL4*) and the Tudor family (*TDRD5*, *TDRD7*, *TDRD9*, *TDRD15*, *TDRKH*).](oncotarget-08-35154-g005){#F5}

DISCUSSION {#s3}
==========

*STK31* is highly conserved in humans, chimpanzees, and gorillas. Previous reports have stated that the STK domain is required for regulating cancer cell differentiation \[[@R14]\] and STK expression is often altered in human cancers \[[@R17]\].

The present study demonstrates that, except the testes, *STK31* is not expressed in normal tissues but aberrantly expressed in PC tissues, indicating that *STK31* is a CT gene in PC. Whether *STK31* is expressed is related to the pathologic stage, new neoplasm status, and prognosis of PC, which might be a new means of aiding clinical diagnosis and estimating the degree of severity. As lower *STK31* expression is beneficial for patients with PC, perhaps attempts should be made to inhibit the expression of *STK31*. These inhibitors of STK31 are akin to a molecular therapeutic target, to improve the survival of patients with PC. There are numerous commercially available inhibitors of STKs now including inhibitors of the *STK31* STK domain \[[@R18]\].

Currently, there are four major mutation driver genes of PC: *KRAS*, *CDKN2A*, *TP53*, and *SMAD4*. However, only about two-thirds of patients with PC carry one or more mutations on these genes. We also found that only 2% of patients with PC carry *STK31* mutations. Interestingly, we found that *STK31* was activated by demethylation, which is also an important mechanism for the reactivation of most CT genes \[[@R9], [@R19], [@R20]\], which is consistent to Yokoe\'s study \[[@R21]\].

In the testis, *STK31* expression is limited to spermatogonia \[[@R22]\], indicating its key role in germ cell differentiation. However, Fok and his group subsequently found that *STK31* could also regulate colon cancer cell differentiation \[[@R14]\]. In this present study, we found that *STK31* interacts with the PIWI subfamily (*PIWIL1*, *PIWIL3*, *PIWIL4*), which is confirmed by co-immunoprecipitation assay *in vivo* and *in vitro* in mice testes \[[@R12]\]. PIWI subfamily comprised of evolutionarily conserved proteins containing both PAZ and Piwi motifs. It plays an important role in stem cell self-renewal, RNA silencing, and translational regulation. And *STK31* also interacts with the Tudor family (*TDRD5*, *TDRD7*, *TDRD9*, *TDRD15*, *TDRKH*), an evolutionarily conserved family of proteins involved in germ cell development. These two families have long been interrelated. *PIWIL1*, *PIWIL3*, and *PIWIL4* act as intrinsic regulators of the self-renewal capacity of germ line and hematopoietic stem cells, and are believed to be involved in cancer development \[[@R23]--[@R26]\]. *TDRD5*, *TDRD9*, and *TDRKH* are essential for PIWI-interacting RNA (piRNA)-mediated retrotransposon silencing in the male germline \[[@R27]--[@R29]\].

In conclusion, *STK31* is a CT gene and is reactivated by demethylation. *STK31* expression is significantly higher in relapsed patients, or patients with advanced pathologic stage or poorer prognosis, suggesting that *STK31* might be of potential clinical value. *STK31* interacts with the PIWI and Tudor families, which suggests that it might play a key role in maintaining genomic instability. Molecular targeting treatment has evolved along with better understanding of the mechanisms of cancer, and *STK31* may be a good molecular therapeutic target in PC.

MATERIALS AND METHODS {#s4}
=====================

Public datasets {#s4_1}
---------------

We used multiple public databases containing data on both normal and PC tissues to evaluate the expression pattern of *STK31*. The GTEx contains information on gene expression in multiple normal tissues, including the pancreas and testis (<http://www.gtexportal.org/home/>) \[[@R30]\]. The HPA presents the expression levels of both RNA and protein in normal and tumor tissues (<http://www.proteinatlas.org/>) \[[@R31]\]. The transcriptional profile and clinical data of PC were obtained from PAAD datasets in TCGA (released on June 1, 2015 <https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp>) \[[@R32]\]. In total, 178 samples had both gene expression and clinical data. Level 3 released gene expression data for RNA-seq was performed RNA-Seq by Expectation Maximization (RSEM). RSEM is an accurate transcript quantification from RNA-Seq data \[[@R33]\].

*STK31* tissue expression pattern {#s4_2}
---------------------------------

*STK31* expression data were extracted from the above databases and the differential expression levels between clinical statuses were analyzed using the chi-square test. Survival analysis was used to evaluate the prognostic role of *STK31* in PC, and log-rank testing was used to determine the significance for Kaplan--Meier analyses to uncover the indication for survival time.

*STK31* regulatory mechanism and gene ontology (GO) analysis {#s4_3}
------------------------------------------------------------

Correlation analysis was performed to establish a relationship between methylation and *STK31* expression, which suggested potential regulation of *STK31*. The role of histone modification in promoter region (2 kb upstream of the STK31) to the STK31 was assessed in UCSC genome browser \[[@R34]\]. The relationship of all other genes (20,531 genes) with *STK31* was assessed in the RNA-seq of TCGA PAAD data, which used the Spearman test and considered genes with Spearman *P* \< 1 × 10^-6^ as *STK31*-related. The GO analysis was executed by DAVID 6.8 Beta \[[@R35]\], which systematically extracts biological pathways from large gene lists. The Functional_Categories (KEYWORDS) and pathway (KEGG pathway) of the *STK31*-related genes were analyzed using DAVID with FDR *P* \< 0.05 (based on the hypergeometric distribution) and count ≥ 2 (number of genes).

Protein--protein interactions (PPI) network analysis {#s4_4}
----------------------------------------------------

The STRING 10.0 \[[@R36]\] database is commonly used to retrieve predicted protein interactions. STRING 10.0 covers a total 2031 organisms and 9,643,763 proteins. All PPI obtained by STRING 10.0 have confidence scores. We searched the *STK31*-interacting genes, and selected genes with a confidence score ≥ 0.4 to construct the PPI network.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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